Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB and Sanofi Aventis confirm availability of Xyzal

UCB and Sanofi Aventis confirm availability of Xyzal

3rd October 2007

UCB and Sanofi Aventis have confirmed that their new once-daily medication to treat allergies is now available by prescription in the US.

Xyzal, an oral antihistamine for use on both indoor and outdoor allergies as well as for chronic idiopathic urticaria, has now been approved for use in adults and children six years and over.

The two companies agreed to launch and co-market Xyzal in the US in September 2006 and it was approved by the Food and Drug Administration in May this year.

Michael S Blaiss, clinical professor of paediatrics and medicine at the University of Tennessee, stated the importance of Xyzal’s availability.

“Allergy patients need a prescription treatment option that works quickly to relieve their suffering,” he said.

He went on to acknowledge that patients would need to consult health professionals as well when developing an allergy treatment plan that would continue to be effective.

Clinical studies using Xyzal have shown it to reduce the symptoms in allergic rhinitis patients as well as significantly reducing the redness, swelling and itching symptoms associated with hives.

In December 2006, Schering-Plough announced the publication of data in the Drug Safety journal claiming that administration with Aerius/Neoclarityn (desloratadine) results in less patient drowsiness than treatment with Xyzal.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.